Study of 9cUAB30 in Healthy Participants

Inclusion criteria

* Healthy volunteer * Karnofsky performance status (PS) 70-100% (ECOG PS 0-1) * WBC ≥ 3,000/mm³ * Platelet count ≥ 100,000mm³ * Hemoglobin \> 10 g/dL * Bilirubin ≤ 1.4 mg/dL * AST ≤ 1.5 times normal * Creatinine normal * Sodium 135-144 mmol/L * Potassium 3.2-4.8 mmol/L * Chloride 85-114 mmol/L * Bicarbonate \> 11 mEQ/dL * Fasting triglycerides ≤ 1.5 times upper limit of normal (ULN) * Fasting cholesterol ≤ 1.5 times ULN * Not pregnant or nursing * No nursing during and for 30 days after completion of study treatment * Negative pregnancy test * Fertile participants must use effective contraception prior to, during, and for 1 month after completion of study treatment * No low-dose progesterone only birth control pills * No concurrent uncontrolled illness including, but not limited to, any of the following: * Ongoing or active infection * Symptomatic congestive heart failure * Unstable angina pectoris * Cardiac arrhythmia * Psychiatricillness or social situation that would limit compliance with study requirements * No history of allergic reactions attributed to compounds of similar chemical or biological composition to retinoids * No other concurrent investigational agents * No concurrent lipid-lowering agents * No concurrent medications that may interact with 9cUAB30 (e.g., St.John's wort, ketoconazole, vitamin A, tetracycline, or oral corticosteroids) * No other concurrent topical or oral retinoids (e.g., retinol, retinal, tretinoin \[Retin-A\], isotretinoin, alitretinoin, etretinate, acitretin,tazarotene, or bexarotene)